Fig. 1: High expression of TRIM25 is associated with recurrence in colorectal cancer.
From: TRIM25 regulates oxaliplatin resistance in colorectal cancer by promoting EZH2 stability

A Analysis of TRIM25 expression in CRC and adjacent normal tissues from publicly available GEO data set (GSE20842), as assessed using a t test. B Representative IHC images of TRIM25 in colorectal tumor or normal tissues. Scale bar, 20 μm. c IHC scores of TRIM25 levels in paired normal and CRC samples are shown as a symbol-line plot. Expression data for normal and tumor tissue from a given individual are linked with dashed lines. Differences were assessed using a paired two-tailed t test. D Western blotting analysis showing the level of TRIM25 in 26 primary tumor tissues from patients with stage III CRC who were treated with OXA-based chemotherapy, including 13 samples from patients who developed recurrence and 13 samples from patients who did not develop recurrence after surgical resection. E Representative IHC images of TRIM25 in 223 CRC tissues with or without recurrence. Scale bar, 200 μm. F Relationship between TRIM25 expression and CRC recurrence, as assessed using a χ2 test. G Comparison of disease-free survival between patients with high or low TRIM25 expression, as assessed using a log-rank test.